Trial reportAmerican journal of respiratory and critical care medicine2011
Regulatory haplotypes in ARG1 are associated with altered bronchodilator response.
Trial report in American journal of respiratory and critical care medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Leukotriene Polymorphisms and Montelukast Response - Ancillary to LoDo Trial
An Efficacy and Safety Study of Levalbuterol, Racemic Albuterol and Placebo in Subjects Twelve Years of Age and Older With Asthma
The Leukotriene Modifier Or Corticosteroid or Corticosteroid-Salmeterol Trial
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- A genome-wide analysis of the response to inhaled β2-agonists in chronic obstructive pulmonary disease.The pharmacogenomics journal · 2016Pooled it
- Diagnostic accuracy of the bronchodilator response in children.The Journal of allergy and clinical immunology · 2013Trial
- IL-9R/Arg1 pathway promotes polyamine metabolism in human airway macrophages.The Journal of allergy and clinical immunology · 2026Article
- Lysosomal acidity and cathepsin L activate eosinophils via ARG1-mediated arginine metabolism in allergic airway inflammation.Nature communications · 2025Article
- Heterogeneity of Treatment Response to Asthma.Advances in experimental medicine and biology · 2023Article
- Beyond eNOS: Genetic influence in NO pathway affecting drug response.Genetics and molecular biology · 2022Article
- Arginase II polymorphisms modify the hypotensive responses to propofol by affecting nitric oxide bioavailability.European journal of clinical pharmacology · 2021Article
- Arginine metabolic control of airway inflammation.JCI insight · 2020Article
- Pharmacogenetic Factors Affecting Asthma Treatment Response. Potential Implications for Drug Therapy.Frontiers in pharmacology · 2019Review
- Proteomic Analysis Provides Insights Into the Therapeutic Effect of GU-BEN-FANG-XIAO Decoction on a Persistent Asthmatic Mouse Model.Frontiers in pharmacology · 2019Article
- Association of increased risk of asthma with elevated arginase & interleukin-13 levels in serum & rs2781666 G/T genotype of arginase I.The Indian journal of medical research · 2018Article
- Influence of arginase polymorphisms and arginase levels/activity on the response to erectile dysfunction therapy with sildenafil.The pharmacogenomics journal · 2018Article
- Article
- [Research advances in gene polymorphisms in biological pathways of drugs for asthma].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2016Review
- Genome-wide association study of short-acting β2-agonists. A novel genome-wide significant locus on chromosome 2 near ASB3.American journal of respiratory and critical care medicine · 2015Article
- Asthma pharmacogenetics and the development of genetic profiles for personalized medicine.Pharmacogenomics and personalized medicine · 2015Review
- Arginase I gene single-nucleotide polymorphism is associated with decreased risk of pulmonary hypertension in bronchopulmonary dysplasia.Acta paediatrica (Oslo, Norway : 1992) · 2014Article
- Integrating omics technologies to study pulmonary physiology and pathology at the systems level.Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology · 2014Review
- Pharmacogenetics: implications of race and ethnicity on defining genetic profiles for personalized medicine.The Journal of allergy and clinical immunology · 2014Review
- Integrative systems biology approaches in asthma pharmacogenomics.Pharmacogenomics · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 6 institutions in 2 countries.
Funding
Abstract
rationaleβ₂-agonists, the most common treatment for asthma, have a wide interindividual variability in response, which is partially attributed to genetic factors. We previously identified single nucleotide polymorphisms in the arginase 1 (ARG1) gene, which are associated with β₂-agonist bronchodilator response (BDR).
objectivesTo identify cis-acting haplotypes in the ARG1 locus that are associated with BDR in patients with asthma and regulate gene expression in vitro.
methodsWe resequenced ARG1 in 96 individuals and identified three common, 5' haplotypes (denoted 1, 2, and 3). A haplotype-based association analysis of BDR was performed in three independent, adult asthma drug trial populations. Next, each haplotype was cloned into vectors containing a luciferase reporter gene and transfected into human airway epithelial cells (BEAS-2B) to ascertain its effect on gene expression. MEASUREMENTS AND MAIN
resultsBDR varied by haplotype in each of the three populations with asthma. Individuals with haplotype 1 were more likely to have higher BDR, compared to those with haplotypes 2 and 3, which is supported by odds ratios of 1.25 (95% confidence interval, 1.03-1.71) and 2.18 (95% confidence interval, 1.34-2.52), respectively. Luciferase expression was 50% greater in cells transfected with haplotype 1 compared to haplotypes 2 and 3.
conclusionsThe identified ARG1 haplotypes seem to alter BDR and differentially regulate gene expression with a concordance of decreased BDR and reporter activity from haplotypes 2 and 3. These findings may facilitate pharmacogenetic tests to predict individuals who may benefit from other therapeutic agents in addition to β(2)-agonists for optimal asthma management. Clinical trial registered with www.clinicaltrials.gov (NCT00156819, NCT00046644, and NCT00073840).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.